The Role of Inflammasomes in Mediating Urological Disease: A Short Literature Review

References

• Kanneganti TD. The inflammasome: firing up innate immunity. Immunolol Rev. 2015;265(1):1–5. doi:10.1111/imr.12297
   PubMed Web of Science ®Google Scholar
• Purves JT, Hughes FM Jr. Inflammasomes in the urinary tract: a disease-based review. Am J Physiol Renal Physiol. 2016;311(4):653–662. doi:10.1152/ajprenal.00607.2015
   Web of Science ®Google Scholar
• Kayagaki N, Wong M, Stowe I, et al. Noncanonical inflammasome activation by intracellular LPS independent of TLR4. Science. 2013;341(6151):1246–1249. doi:10.1126/science.1240248
   PubMed Web of Science ®Google Scholar
• Zahid A, Li B, Kombe J, Arnaud J, Tengchuan T. Pharmacological inhibitors of the NLRP3 inflammasome. Front Immunol. 2019;10:2538. doi:10.3389/fimmu.2019.02538
   PubMed Web of Science ®Google Scholar
• Poli G, Egidi MG, Cochetti G, Brancorsini S, Mearini E. Relationship between cellular and exosomal miRNAs targeting NOD-like receptors in bladder cancer: preliminary results. Minerva Urol Nefrol. 2020;72(2):207–213. doi:10.23736/S0393-2249.19.03297-1
   PubMed Web of Science ®Google Scholar
• Barbarino M, Cesari D, Bottaro M, et al. PRMT5 silencing selectively affects MTAP-deleted mesothelioma: in vitro evidence of a novel promising approach. J Cell Mol Med. 2020;24:5565–5577.
   PubMed Web of Science ®Google Scholar
• Moher D, Shamseer L, Clarke M. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015 statement. System Rev. 2014;4:1.
   Google Scholar
• Shamseer L, Moher D, Clarke M. Preferred reporting items for systematic review and meta-analysis protocols (PRISMA-P) 2015: elaboration and explanation. BMJ. 2015;349:7647. doi:10.1136/bmj.g7647
   PubMed Web of Science ®Google Scholar
• Inouye B, Hughes F, Sexton S, Purves JT. The emerging role of inflammasomes as central mediators in inflammatory bladder pathology. Curr Urol. 2018;11:57–72. doi:10.1159/000447196
   PubMedGoogle Scholar
• Baker PJ, Boucher D, Bierschenk D, et al. NLRP3 inflammasome activation downstream of cytoplasmic LPS recognition by both caspase-4 and caspase-5. Eur J Immunol. 2015;45(10):2918–2926. doi:10.1002/eji.201545655
   PubMed Web of Science ®Google Scholar
• Verma V, Gupta S, Kumar P, et al. Involvement of NLRP3 and NLRC4 inflammasome in uropathogenic e. coli mediated urinary tract infections. Front Microbiol. 2019;10:3–6. doi:10.3389/fmicb.2019.02020
   PubMed Web of Science ®Google Scholar
• Chen KW, Demarco B, Heilig R, et al. Extrinsic and intrinsic apoptosis activate pannexin-1 to drive NLRP3 inflammasome assembly. EMBO J. 2019;38:e101638. doi:10.15252/embj.2019101638
   PubMed Web of Science ®Google Scholar
• Russo A, Behl B, Banerjee I, Rathinam V. Emerging insights into noncanonical inflammasome recognition of microbes. J Mol Biol. 2018;430(2):207–216. doi:10.1016/j.jmb.2017.10.003
   PubMed Web of Science ®Google Scholar
• Chen N, Ou Z, Zhang W, et al. Cathepsin B regulates non-canonical NLRP3 inflammasome pathway by modulating activation of caspase-11 in Kupffer cells. Cell Prolif. 2018;51(6):e12487. doi:10.1111/cpr.12487
   PubMed Web of Science ®Google Scholar
• Wang Y, Sedlacek AL, Pawaria S, et al. Cutting edge: the heat shock protein gp96 activates inflammasome-signaling platforms in APCs. J Immunol. 2018;201(8):2209–2214. doi:10.4049/jimmunol.1800505
   PubMed Web of Science ®Google Scholar
• Chung H, Vilaysane A, Lau A, et al. NLRP3 regulates a non-canonical platform for caspase-8 activation during epithelial cell apoptosis. Cell Death Diff. 2016;23(8):1331–1346. doi:10.1038/cdd.2016.14
   PubMed Web of Science ®Google Scholar
• Vilaysane A, Chun J, Seamone M, et al. The NLRP3 inflammasome promotes renal inflammation and contributes to CKD. J Am Soc Nephrol. 2010;21:1732–1744.
   PubMed Web of Science ®Google Scholar
• Ermer T, Eckardt KU, Aronson PS, Knauf F. Oxalate, inflammasome, and progression of kidney disease. Curr Opin Nephrol Hypertens. 2016;25(4):363–371. doi:10.1097/MNH.0000000000000229
   PubMed Web of Science ®Google Scholar
• Martine P, Rébé C. Heat shock proteins and inflammasomes. Int J Mol Sci. 2019;20(18):4508. doi:10.3390/ijms20184508
   PubMed Web of Science ®Google Scholar
• Martine P, Chevriaux A, Derangère V, et al. HSP70 is a negative regulator of NLRP3 inflammasome activation. Cell Death Dis. 2019;10(4):256. doi:10.1038/s41419-019-1491-7
   PubMed Web of Science ®Google Scholar
• Augé C, Chene G, Dubourdeou M, et al. Relevance of the cyclophosphamide-induced cystitis model for pharmacological studies targeting inflammation and pain of the bladder. Euro J Pharm. 2013;707(1–3):32–40. doi:10.1016/j.ejphar.2013.03.008
   PubMed Web of Science ®Google Scholar
• Karan D, Dubey S. From inflammation to prostate cancer: the role of inflammasomes. Adv Urol. 2016;18:314–372.
   Google Scholar
• Arrellano-Valdez F, Osario M, Arroyo C, Vega E. A comprehensive review of urologic complications in patients with diabetes. Spri Plus. 2014;3(1):549–551. doi:10.1186/2193-1801-3-549
   PubMed Web of Science ®Google Scholar
• Kesavardhana S, Kanneganti TD. Mechanisms governing inflammasome activation, assembly and pyroptosis induction. Int Immunol. 2017;29(5):201–210. doi:10.1093/intimm/dxx018
   PubMed Web of Science ®Google Scholar
• Hughes FM, Hill HM, Wood CM, et al. The NLRP3 inflammasome mediates inflammation produced by bladder outlet obstruction. J Urol. 2016;195:1598–1605.
   PubMed Web of Science ®Google Scholar
• Simmering JE, Tang F, Cavanaugh JE, Polgreen LA, Polgreen PM. The increase in hospitalizations for urinary tract infections and the associated costs in the United States, 1998–2011. Open Forum Infect Dis. 2017;4(1):ofw281. doi:10.1093/ofid/ofw281
   PubMed Web of Science ®Google Scholar
• Hughes FM, Vivar N, Kennis J, et al. Inflammasomes are important mediators of cyclophosphamide-induced bladder inflammation. Am J Physiol Renal Physiol. 2014;306:3–14.
   Web of Science ®Google Scholar
• Wu D, Chen Y, Sun Y, et al. Target of MCC950 in inhibition of NLRP3 inflammasome activation: a literature review. Inflamm. 2020;43(1):17–23. doi:10.1007/s10753-019-01098-8
   Web of Science ®Google Scholar
• Ju M, Bi J, Wei Q, et al. Pan-cancer analysis of NLRP3 inflammasome with potential implications in prognosis and immunotherapy in human cancer. Brief Bioinform. 2021;22(4):bbaa345. doi:10.1093/bib/bbaa345
   PubMed Web of Science ®Google Scholar
• Ponomareva L, Liu H, Duan X, et al. AIM2, an IFN-inducible cytosolic DNA sensor, in the development of benign prostate hyperplasia and prostate cancer. Mol Cancer Res. 2013;11(10):1193–1202. doi:10.1158/1541-7786.MCR-13-0145
   PubMed Web of Science ®Google Scholar
• Patel N, Brown RD, Sarkissian C, De S, Monga M. Quality of life and urolithiasis: the patient - reported outcomes measurement information system (PROMIS). Int Braz J Urol. 2017;43(5):880–886. doi:10.1590/s1677-5538.ibju.2016.0649
   PubMed Web of Science ®Google Scholar